Conning Inc. Reduces Position in Zoetis Inc. $ZTS

Conning Inc. lessened its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 5.2% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,871 shares of the company’s stock after selling 158 shares during the quarter. Conning Inc.’s holdings in Zoetis were worth $448,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in ZTS. Nova Wealth Management Inc. acquired a new position in Zoetis in the 1st quarter valued at about $25,000. 1248 Management LLC bought a new stake in shares of Zoetis during the first quarter worth approximately $27,000. Saudi Central Bank acquired a new position in shares of Zoetis in the first quarter valued at approximately $29,000. Cornerstone Planning Group LLC increased its stake in shares of Zoetis by 79.3% during the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock worth $30,000 after purchasing an additional 88 shares during the period. Finally, REAP Financial Group LLC lifted its holdings in Zoetis by 201.5% during the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after purchasing an additional 131 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

ZTS has been the topic of several recent research reports. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a research report on Wednesday. Piper Sandler raised their price target on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Argus reissued a “buy” rating and issued a $190.00 price objective on shares of Zoetis in a report on Tuesday, September 9th. Leerink Partnrs cut shares of Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Finally, Leerink Partners cut Zoetis from an “outperform” rating to a “market perform” rating and cut their price target for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Four investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, Zoetis currently has an average rating of “Hold” and an average target price of $196.71.

Zoetis Trading Down 1.6%

Zoetis stock opened at $141.05 on Friday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. Zoetis Inc. has a fifty-two week low of $139.34 and a fifty-two week high of $196.55. The stock has a market cap of $62.51 billion, a P/E ratio of 24.28, a PEG ratio of 2.26 and a beta of 0.90. The firm’s fifty day moving average price is $149.24 and its 200-day moving average price is $154.41.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping the consensus estimate of $1.62 by $0.14. The business had revenue of $2.46 billion during the quarter, compared to analysts’ expectations of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm’s revenue was up 4.2% on a year-over-year basis. During the same period in the previous year, the business earned $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.4%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis’s payout ratio is currently 34.42%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.